Survivors of Breast or colorectal cancer who are 5-10 years cancer free
Conditions
Interventions
Group 1: Survivors of breast or colorectal cancer who are 5-10 years cancer free
Sponsors
University of Bern
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: A positive breast or colorectal cancer diagnosis at least 5 years but no more than 10 years before Visit 1, no new cancer diagnoses during this time period, except for specific non-melanoma skin cancers and superficial bladder cancer or cancer in-situ. Patients who received/are still receiving adjuvant therapy may be included
Exclusion criteria
Exclusion criteria: - Confirmed diagnosis of chronic hepatic disease - Pregnancy, or suspected pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of breast cancer (BC) and colorectal cancer (CRC) survivors detected with a high probability of fMASLD, defined as having a high probability according to the FAST score (= 0.67), or an uncertain probability according to the FAST score (> 0.35 and < 0.67) and a high probability according to the MAST score (= 0.242). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To identify participant-, tumor-, and treatment- related factors associated with fMASLD and its precursor states, describing the distribution and activity of fMASLD within the study population. Participant-specific endpoints include age, sex, body mass index (BMI), body shape index (ABSI) and waist circumference. Tumor-specific endpoints include histological type, tumor subtype, and tumor stage according to standard classification systems. Treatment-specific endpoints include the type of treatment received, number of treatment cycles, and time intervals between treatment modalities. 2. To assess the utility of the MAST score as an additional non-invasive marker of fibrosis risk. | — |
Countries
Switzerland
Contacts
Public ContactEva Segelov
University of Bern
Outcome results
None listed